CLB (Core Laboratories) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLB Core Laboratories Inc CLB
62 GF Score
Price $11.25
GF Value $16.97
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Core Laboratories Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Core Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $11.9 Mil. Core Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $153.2 Mil. Core Laboratories's annualized EBITDA for the quarter that ended in Jun. 2026 was $52.6 Mil. Core Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 3.14.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Core Laboratories's Debt-to-EBITDA or its related term are showing as below:

CLB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.85   Med: 2.38   Max: 3.92
Current: 2.64

During the past 13 years, the highest Debt-to-EBITDA Ratio of Core Laboratories was 3.92. The lowest was -5.85. And the median was 2.38.

CLB's Debt-to-EBITDA is ranked worse than
61.98% of 718 companies
in the Oil & Gas industry
Industry Median: 1.825 vs CLB: 2.64

Core Laboratories  (NYSE:CLB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Core Laboratories Debt-to-EBITDA Related Terms


Core Laboratories Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Core Laboratories's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Core Laboratories Debt-to-EBITDA Chart

Core Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Core Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CLB vs OIS, EROK, NGS: Debt-to-EBITDA Comparison

For the Oil & Gas Equipment & Services subindustry, Core Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Core Laboratories Debt-to-EBITDA vs Oil & Gas Industry

For the Oil & Gas industry and Energy sector, Core Laboratories's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Core Laboratories's Debt-to-EBITDA falls into.


CLB
62GF Score
Core Laboratories Inc CLB
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Core Laboratories Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Core Laboratories's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(11.456000000122 + 152.56400000163) / 71.771000000785
=2.29

Core Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(11.94000000008 + 153.17500000102) / 52.644000000376
=3.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is Core Laboratories (CLB) Overvalued in 2026?

Based on GuruFocus' analysis, Core Laboratories stock appears to be undervalued. The current stock price of $11.25 is trading 33.7% below its estimated GF Value™ of $16.97. GuruFocus considers Core Laboratories to be Significantly Undervalued.

Key valuation signals for CLB:

  • Debt-to-EBITDA:
  • GF Value™: $16.97 vs. price of $11.25 (33.7% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the CLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Core Laboratories Business Description

Industry EnergyOil & Gas
Other Exchanges HJ1:Germany
Address 6316 Windfern Road, Houston, TX, USA, 77040
Core Laboratories Inc is a providers of proprietary and patented reservoir description and production enhancement services and products to the oil and gas industry, through client relationships. The company operates its business in two segments; Reservoir Description, and Production Enhancement. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services. The company generates majority of its revenue from Reservoir Description segment.
62GF Score

Get the complete analysis for CLB

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.25
Price
$16.97
GF Value